Diagonal Bio AB (publ)

OM:DIABIO Stock Report

Market Cap: SEK 9.6m

Diagonal Bio Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Karin Wehlin

Chief executive officer

SEK 64.0k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3.9yrs

Recent management updates

Recent updates

CEO

Karin Wehlin (61 yo)

less than a year

Tenure

SEK 64,000

Compensation

Ms. Karin Wehlin, MBA is Chief Executive Officer of Diagonal Bio AB (publ) since February 2024 and was its Director since 2023 until June 12, 2024 and served as its Interim CEO from November 23, 2023 to Fe...

Leadership Team

NamePositionTenureCompensationOwnership
Karin Wehlin
Chief Executive Officerless than a yearSEK 64.00kno data
Kushagr Punyani
Tech Advisorno dataSEK 100.00k0.50%
SEK 47.5k
Andreas Nyberg
Founder & Chief Scientific Officer4.9yrsno data0.23%
SEK 22.2k
Johan Kallstrand
Founding Partnerno datano datano data
Fata Mrsic
Chief Financial Officerless than a yearno datano data

0.8yrs

Average Tenure

Experienced Management: DIABIO's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Kushagr Punyani
Tech Advisor4.9yrsSEK 100.00k0.50%
SEK 47.5k
Kerstin Jakobsson
Chair of the Board3.9yrsSEK 212.00kno data
Sam Whitehouse
Member of Advisory Boardno datano datano data
Edvard Hall
Director3.9yrsno datano data
Tim Christensen
Member of Advisory Boardno datano datano data

3.9yrs

Average Tenure

39yo

Average Age

Experienced Board: DIABIO's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 05:30
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diagonal Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution